Early subcutaneous basal insulin with intravenous insulin infusion for diabetic ketoacidosis management: A systematic review and meta‐analysis of randomised controlled trials
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70276 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Kitti Thammakosol und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Diabetic Ketoacidosis, Hypoglycemic Agents, Insulin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Aims
To evaluate the effectiveness and safety of early initiation of subcutaneous (SC) basal insulin in combination with intravenous insulin infusion (IVII), compared with IVII alone, for the management of diabetic ketoacidosis (DKA). Materials and Methods A systematic search of PubMed, Embase, Scopus, and the Cochrane Library was conducted to identify randomised controlled trials (RCTs) comparing early initiation of long‐ or ultra‐long‐acting basal insulin plus IVII versus IVII alone in DKA management. Studies published up to 6 September 2025, were included. Meta‐analysis was performed using mean difference (MD) for continuous outcomes and risk ratio for dichotomous outcomes, both with a 95% confidence interval (CI). The primary outcome was time to DKA resolution. Secondary outcomes included total intravenous insulin use, rebound hyperglycemia, hypoglycemia, hypokalemia, length of hospital stay (LOS), and mortality. A one‐stage individual participant data meta‐analysis was also conducted when individual‐level data were available.
Results
Eight RCTs including 468 participants (256 receiving early SC basal insulin plus IVII; 212 receiving IVII alone) were included. Baseline characteristics were comparable across studies. Early SC basal insulin significantly reduced time to DKA resolution (MD −4.02 h, 95%CI −5.52 to −2.52, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
- Department of Medicine, Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand.
- Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
- Department of Internal Medicine, Chiang Rai Prachanukroh Hospital, Chiang Rai, Thailand.
ORCID-Profile: Chutintorn Sriphrapradang
Zitieren
APA
Thammakosol, K., Vongtangton, P., Numthavaj, P., Auttara-Atthakorn, A., & Sriphrapradang, C. (2026). Early subcutaneous basal insulin with intravenous insulin infusion for diabetic ketoacidosis management: A systematic review and meta‐analysis of randomised controlled trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70276
Vancouver
Thammakosol K, Vongtangton P, Numthavaj P, Auttara-Atthakorn A, Sriphrapradang C. Early subcutaneous basal insulin with intravenous insulin infusion for diabetic ketoacidosis management: A systematic review and meta‐analysis of randomised controlled trials. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70276
BibTeX
@article{Thammakosol2026,
author = {Thammakosol, Kitti and Vongtangton, Patteera and Numthavaj, Pawin and Auttara-Atthakorn, Arunrat and Sriphrapradang, Chutintorn},
title = {Early subcutaneous basal insulin with intravenous insulin infusion for diabetic ketoacidosis management: A systematic review and meta‐analysis of randomised controlled trials},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70276}
}
EUVIMED